Published in Osteoporos Int on February 24, 2004
Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet (2013) 1.64
The epidemiology of distal radius fractures. Hand Clin (2012) 1.40
Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int (2008) 1.04
The effect of LRP5 polymorphisms on bone mineral density is apparent in childhood. Calcif Tissue Int (2007) 1.00
Determinants of peak bone mineral density and bone area in young women. J Bone Miner Metab (2005) 0.99
Bone mineral density at the hip in Norwegian women and men--prevalence of osteoporosis depends on chosen references: the Tromsø Study. Eur J Epidemiol (2009) 0.93
Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do? Patient Prefer Adherence (2012) 0.93
Impact of smoking on bone mineral density and bone metabolism in elderly men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int (2010) 0.91
An investigation into the relationship between soft tissue body composition and bone mineral density in a young adult twin sample. J Bone Miner Res (2011) 0.88
Bone health and the female athlete triad in adolescent athletes. Phys Sportsmed (2011) 0.85
Quantitative genetics of cortical bone mass in healthy 10-year-old children from the Fels Longitudinal Study. Bone (2006) 0.85
Oral contraceptive use and bone density in adolescent and young adult women. Contraception (2010) 0.84
Pathological fractures in paediatric patients with inflammatory bowel disease. Eur J Pediatr (2013) 0.84
Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients. BMC Musculoskelet Disord (2010) 0.83
Age-specific effects of estrogen receptors' polymorphisms on the bone traits in healthy fertile women: the BONTURNO study. Reprod Biol Endocrinol (2009) 0.83
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Racial difference in the correlates of bone mineral content/density and age at peak among reproductive-aged women. Osteoporos Int (2009) 0.78
Severity and pattern of bone mineral loss in endocrine causes of osteoporosis as compared to age-related bone mineral loss. J Postgrad Med (2016) 0.78
Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex: results of the 2009-2010 Korean National Health and Nutrition Examination Survey (KNHANES). J Bone Miner Metab (2015) 0.77
The Relationship Between Greater Prepubertal Adiposity, Subsequent Age of Maturation, and Bone Strength During Adolescence. J Bone Miner Res (2016) 0.77
Skeletal integrity and visceral transplantation. Am J Transplant (2010) 0.77
Reference equations for ultrasound bone densitometry of the radius in Central European children and adolescents. Osteoporos Int (2014) 0.76
Age curves of bone mineral density at the distal radius and calcaneus in Koreans. J Bone Miner Metab (2009) 0.76
Effect of a program of short bouts of exercise on bone health in adolescents involved in different sports: the PRO-BONE study protocol. BMC Public Health (2015) 0.76
Smoking among premenopausal women is associated with increased risk of low bone status: the JPOS Study. J Bone Miner Metab (2009) 0.76
Physiological employment standards IV: integration of women in combat units physiological and medical considerations. Eur J Appl Physiol (2012) 0.75
The Association between Weight Gain/Restoration and Bone Mineral Density in Adolescents with Anorexia Nervosa: A Systematic Review. Nutrients (2016) 0.75
Insulin and bone health in young adults: The mediator role of lean mass. PLoS One (2017) 0.75
Different reference BMDs affect the prevalence of osteoporosis. J Bone Miner Metab (2015) 0.75
Exercise and bone health across the lifespan. Biogerontology (2017) 0.75
Establishment of peak bone mineral density in Southern Chinese males and its comparisons with other males from different regions of China. J Bone Miner Metab (2007) 0.75
Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int (2009) 0.75
Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child (1995) 12.65
New approaches for interpreting projected bone densitometry data. J Bone Miner Res (1992) 3.12
Adolescents' self-assessment of sexual maturation. Pediatrics (1980) 3.06
Bone gain in young adult women. JAMA (1992) 2.73
Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab (1991) 2.56
Differential effect of race on the axial and appendicular skeletons of children. J Clin Endocrinol Metab (1998) 2.50
Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab (1992) 2.42
Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab (1991) 2.27
Reduced bone mass in daughters of women with osteoporosis. N Engl J Med (1989) 1.70
The two faces of growth: benefits and risks to bone integrity. Osteoporos Int (1994) 1.62
Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. Bone Miner (1992) 1.61
Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab (1997) 1.57
Evaluation of cortical bone by computed tomography. J Bone Miner Res (1996) 1.55
Comparison of rates of bone loss from the spine measured using two manufacturers' densitometers. J Bone Miner Res (1995) 1.42
Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int (1992) 1.41
Gender differences in vertebral body sizes in children and adolescents. Radiology (1994) 1.41
Sex differences in age-related remodeling of the femur and tibia. J Orthop Res (1988) 1.34
Volumetric bone mineral density in normal subjects, aged 5-27 years. J Clin Endocrinol Metab (1996) 1.33
Influences on skeletal mineralization in children and adolescents: evidence for varying effects of sexual maturation and physical activity. J Pediatr (1994) 1.32
Bone densitometry in Canadian children 8-17 years of Age. Calcif Tissue Int (1996) 1.26
Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone (1990) 1.23
Regional body fat distribution in relation to pubertal stage: a dual-energy X-ray absorptiometry study of New Zealand girls and young women. Am J Clin Nutr (1996) 1.23
The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab (2001) 1.22
Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner (1990) 1.21
The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest (1999) 1.21
Peak trabecular vertebral density: a comparison of adolescent and adult females. Calcif Tissue Int (1988) 1.21
Fracture site-specific deficits in bone size and volumetric density in men with spine or hip fractures. J Bone Miner Res (2001) 1.18
The development of metaphyseal cortex--implications for distal radius fractures during growth. J Bone Miner Res (2001) 1.18
Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone (2000) 1.17
Vertebral bone mass, size, and volumetric density in women with spinal fractures. J Bone Miner Res (1999) 1.16
Vertebral size in elderly women with osteoporosis. Mechanical implications and relationship to fractures. J Clin Invest (1995) 1.15
Structural and cellular changes during bone growth in healthy children. Bone (2000) 1.11
Studies on the potential mediators of skeletal changes occurring during puberty in girls. J Clin Endocrinol Metab (1999) 1.09
Differential effect of gender on the sizes of the bones in the axial and appendicular skeletons. J Clin Endocrinol Metab (1997) 1.08
Sexual dimorphism in human vertebral body shape. J Anat (1984) 1.08
The contribution of reduced peak accrual of bone and age-related bone loss to osteoporosis at the spine and hip: insights from the daughters of women with vertebral or hip fractures. J Bone Miner Res (2001) 1.05
Bone mineral density and bone size in men with primary osteoporosis and vertebral fractures. Calcif Tissue Int (1998) 1.03
Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res (1999) 1.00
Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int (1994) 0.99
Rates of growth and loss of bone mineral in the spine and femoral neck in white females. Osteoporos Int (1999) 0.98
Sitting height and subischial leg length centile curves for boys and girls from Southeast England. Ann Hum Biol (2002) 0.96
Heterogeneity in the growth of the axial and appendicular skeleton in boys: implications for the pathogenesis of bone fragility in men. J Bone Miner Res (2000) 0.95
Bone mass and structure at the hip in men and women over the age of 60 years. Osteoporos Int (1998) 0.95
Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res (1994) 0.95
Differential effects of gonadal function on bone histomorphometry in male and female rats. J Bone Miner Res (1989) 0.95
Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab (1992) 0.93
The effects of gonadectomy on bone size, mass, and volumetric density in growing rats are gender-, site-, and growth hormone-specific. J Bone Miner Res (1999) 0.92
Quantitative histomorphometric analysis of the human growth plate from birth to adolescence. Bone (2000) 0.90
Cancellous bone structure in the growing and aging lumbar spine in a historic Nubian population. Calcif Tissue Int (1997) 0.84
Development of mass, density, and estimated mechanical characteristics of bones in Caucasian females. J Bone Miner Res (1996) 0.82
Bone mineral mass consolidation in young British adults. J Bone Miner Res (1996) 0.81
The effect of ovariectomy on periosteal bone formation and bone resorption in adult rats. Bone Miner (1993) 0.78
Anomalies in the measurement of changes in bone mineral density of the spine by dual-energy X-ray absorptiometry. Calcif Tissue Int (1998) 0.78
Heterogeneity of growth of bone in children at the spine, radius and total skeleton. Growth Dev Aging (1991) 0.77
Evaluation of cortical thickness and bone density by roentgen microdensitometry in growing males and females. Eur J Pediatr (1996) 0.77
Continuing bone expansion and increasing bone loss over a two-decade period in men and women from a total community sample. Am J Hum Biol (1992) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab (2010) 2.29
Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum (2008) 2.26
Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res (2004) 2.21
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. N Engl J Med (2016) 2.15
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res (2012) 1.70
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab (2004) 1.69
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab (2005) 1.68
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Retracted Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA (2011) 1.57
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res (2011) 1.52
Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res (2003) 1.50
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.50
Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. J Bone Miner Res (2013) 1.50
Supine vs decubitus lateral patient positioning in vertebral fracture assessment. J Clin Densitom (2012) 1.46
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc (2004) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone (2009) 1.26
Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int (2008) 1.26
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab (2010) 1.21
Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Orthop Res (2005) 1.19
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab (2008) 1.16
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone (2004) 1.14
Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res (2009) 1.13
Bone mineral density and biochemical markers of bone turnover in aseptic loosening after total hip arthroplasty. J Orthop Res (2003) 1.13
Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches. J Bone Miner Res (2008) 1.11
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med (2011) 1.10
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res (2005) 1.06
Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res (2011) 1.06
Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. J Bone Miner Res (2008) 1.06
Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res (2011) 1.05
Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone (2013) 1.05
Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. J Bone Miner Res (2003) 1.05
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 1.03
Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab (2003) 1.03
Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum Mol Genet (2014) 1.02
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res (2014) 1.01
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res (2010) 1.00
Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res (2005) 0.99
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab (2013) 0.98
Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab (2002) 0.98
Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int (2005) 0.98
Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J Bone Miner Res (2007) 0.96
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res (2013) 0.96
Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res (2011) 0.96
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer (2007) 0.95
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab (2014) 0.95
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab (2012) 0.92
The discriminative ability of peripheral and axial bone measurements to identify proximal femoral, vertebral, distal forearm and proximal humeral fractures: a case control study. Osteoporos Int (2005) 0.92
Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli. J Orthop Res (2010) 0.92
Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Miner Res (2009) 0.92
Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res (2015) 0.91
Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up. Am J Clin Nutr (2008) 0.91
Statistical shape and appearance models in osteoporosis. Curr Osteoporos Rep (2014) 0.89
Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res (2003) 0.89
Precision of high-resolution peripheral quantitative computed tomography measurement variables: influence of gender, examination site, and age. Calcif Tissue Int (2013) 0.89
Vitamin D status in professional ballet dancers: winter vs. summer. J Sci Med Sport (2013) 0.88
Comparison of densitometric and radiographic vertebral fracture assessment using the algorithm-based qualitative (ABQ) method in postmenopausal women at low and high risk of fracture. J Bone Miner Res (2008) 0.87
Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res (2005) 0.87
Influence of bone quality on the strength of internal and external fixation of tibial plateau fractures. J Orthop Res (2006) 0.87
The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone (2009) 0.87
Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc (2003) 0.86
Distribution of bone density in the proximal femur and its association with hip fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res (2012) 0.86
A novel EXT1 splice site mutation in a kindred with hereditary multiple exostosis and osteoporosis. J Clin Endocrinol Metab (2005) 0.86
Variation in the secreted frizzled-related protein-3 gene and risk of osteolysis and heterotopic ossification after total hip arthroplasty. J Orthop Res (2007) 0.86
Bone markers and current laboratory assays. Cancer Treat Rev (2006) 0.85
Heart drugs that affect bone. Trends Endocrinol Metab (2011) 0.85